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program expansion. The health insurance exchanges will
act as marketplaces for people to shop for and compare
health insurance plans in their state. There are three models
of health insurance exchanges: federally facilitated, state
run and partnership exchanges that have input from both
the state and federal governments. Each state chose to
create their own exchange or to have the federal govern-
ment create and operate their state exchange. The ex-
changes present an opportunity for people to access
affordable health insurance through federal tax credits that
will subsidize premiums for individuals and families up to
400 percent of the federal poverty level (FPL). The ex-
changes are expected to enroll 7 million people in the ﬁrst
year of the ACA. Each exchange will offer a variety of qual-
iﬁed health plans (QHP) that are approved by the state and/
or the US Department of Health and Human Services (HHS).
Every QHP and non-grandfathered commercial health in-
surance plan is mandated to include a minimum level of
coverage known as an essential health beneﬁt (EHB) pack-
age selected by each state. Information was collected on
each state’s EHB plan to determine coverage of hemato-
poietic cell transplantation (HCT), and was analyzed for the
level of HCT beneﬁts with consideration of the Recom-
mended Beneﬁt Design For HCT developed by the National
Marrow Donor Program (NMDP) (www.payor.bethematch-
clinical.org). States were then divided into three categories:
poor coverage, fair coverage and excellent coverage. Eleven
states had poor coverage, 12 states had fair coverage and 28
states had excellent coverage included in their EHBs. While
access to health insurance is expanding, it is important that
coverage of HCT meets levels prescribed in the Recom-
mended Beneﬁt Design For HCT. Additionally, states were
able to expand their state Medicaid programs to include
adults up to 138 percent of the FPL. To date, twenty-ﬁve
states are expanding their Medicaid programs, resulting in
increased access for low-income adults in their states. In
states that expanded their Medicaid programs, 31,587,000
adults are now eligible to access to health insurance
coverage through Medicaid (Kaiser Family Foundation). A
study done by the NMDP provides HCT incidence rates that
translates to a possible 2,148 Medicaid patients needing an
allogeneic HCT following Medicaid expansion by states that
have already voted to expand in the ﬁrst year of ACA
implementation. Transplant centers will need to under-
stand how their state operates in each of these three aspects
in order to provide patients with access to HCT in 2014 and
beyond.161
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Background:Match related donors (MRDs) have long been a
critical source of stem cells for patients needing an allogeneic
transplant. In both our center and across the country,
approximately 30% of patients needing an allogeneic trans-
plant will have a matched sibling who can serve as their
donor. While the National Marrow Donor Program (NMDP)
and other donor registries have done extensive research in to
the donor experience for unrelated donors, much less is
known about the experience of donors who are related to thepatient. As part of an effort to improve our services to these
patients, we implemented a donor satisfaction survey spe-
ciﬁcally targeting these donors.
Methods: We assessed both the current hospital patient
survey and the current NMDP donor survey and designed a
survey that would be delivered to adult peripheral blood and
marrow MRDs on the ﬁrst day of collection. We assessed
satisfaction with medical care, effectiveness of administra-
tive coordination efforts, and barriers to donation. We then
reviewed individual surveys and compiled the feedback to
assess needed changes.
Results: In the ﬁrst 6 months, we distributed the survey to
44 patients and received a 50% response rate. Our overall
satisfaction rating was quite high (4.9 out of 5), with
approximately 35% of patients reporting no signiﬁcant bar-
riers to donation. The top concerns for our donors included
worry about the patient, ability to take time off to donate,
travel, and fear of pain or other requirements of the
procedure.
Conclusion: The feedback from the donor satisfaction survey
has been valuable both for our program and for staff morale.
The feedback has been overwhelmingly positive, and our
donor comments are shared with the staff quarterly. A
committee has been formed to review donor feedback and
identify areas for improvement. Going forward we hope to
expand this survey to include pediatric patients, and to
develop new donor material tailored to the feedback we’ve
received.162
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Informed Consent for transplant patients is not only a
requirement by law but an integral part of the patient edu-
cation. Transplant centers often use treatment plans for
standard of care. It is a daunting challenge to maintain and
update treatment plan consent forms.
Over the past 20 years, transplant centers have diversiﬁed
and now use multiple conditioning and graft versus host
disease (GVHD) prophylaxis regimens. In transplant centers
that have been in operation for many years, the use of con-
sents for standard of care treatment plans have been
augmented and changed as needed over time. These changes
are due to the introduction of novel therapies, newly iden-
tiﬁed side effects, changes in regulatory and legal re-
quirements and standardization of terminology.
Standardizing the language of consents presents several
dilemmas.
 Should we try to create a treatment plan consent that
could be used for multiple treatment plans?
◦ Will this be confusing for patients?
◦ Will physicians forget to check the boxes for speciﬁc
drugs that are being used?
 Should we describe side effects by organ system or by
drug or both?
 Should we list side effects in a table?
 Should we incorporate blank spaces for personalized
information to be completed by the MD at the time of
consent?
◦ Will this be more cumbersome for physicians?
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 What is the easiest way to present this information?
 What is the most readable format?
At our center, we developed a unique approach to enable the
swift update of treatment plan consents and to homogenize
the language employed in consents for our patients.
Employing tools in Microsoft Word, we created templated
paragraphs that could be inserted into different documents.
These master paragraphs can be changed and when changed
will automatically update the wording in all the other doc-
uments to which they have been linked.
We createdmaster paragraphs or modules for each section of
the consent and for allogeneic and autologous transplant
consents. Our “Consentapedia” includes sections for each
conditioning or GVHD drug, potential side effects of each
drug stratiﬁed by likelihood of occurrence, risks associated
with the various procedures involved in transplant,
frequently asked questions such as beneﬁts of treatment,
language regarding privacy and conﬁdentiality and other
required information.
Ultimately, we were easily able to create standardized con-
sent forms for over 27 treatment plans. This system facili-
tates the editing of consent forms allowing us to keep them
current while maximizing staff resources. It standardizes the
language for patients and provides consistent patient edu-
cation. It also allows for ease in translation to other lan-
guages. This innovation is simple for other transplant centers
to adopt. This is a quality improvement initiative that pro-
vides beneﬁts to our practice and is feasible and applicable
across other disciplines.
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Water Sampling for Legionella: Managing Positive Results
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Background: Stem cell transplant patients pose major
challenges for preventing infections and infection associated
mortality. The CDC and FACT-JACIE recommend periodic
sampling of water supply sources for microbial contamina-
tion, including Legionella, as an infection prevention strategy.
Sarah Cannon at Tristar Centennial Medical Center is
housed in a building constructed in the 1960s Water comes
from the city of Nashville via a complex plumbing system of
storage towers and risers. 2006, the BMT program began
sampling for microbial contamination. 2007, samples tested
positive for Legionellawith no actual patient infections.
January 2008, a secondary Chlorine Dioxide (ClO2) disin-
fection system was installed to chemically treat the water.
The system analyzes biocide levels and transmits readings
to a central station. Concentrations of ClO2 are adjusted to
keep biocide levels within speciﬁed limits. May 2008 to
September 2012, all samples were negative.
Problem: December 2012, one sample tested positive, <1
CFU/mL for Legionella, not the pneumophiliaspecies most
linked to illness. April 2013, two samples test trace positive
from the Hematologic Malignancy unit connected to the BMT
unit. Of note, construction was ongoing within a block with
several disruptions to the lines feeding water storage towers.
Department leaders hired after installation of the disinfec-
tion system had limited knowledge of managing positive
samples. Communication of the results, implementing in-
terventions and follow-up was disjointed. A written action
plan was not available, necessitating multiple emails, phone
calls and meetings.Intervention: December 2012, the affected room was taken
out of service. A work team met to review options with
members from infectious disease, administration, nursing,
infection prevention, quality/risk management, facility en-
gineering, and the water disinfection system vendor. A
thermal eradication and hyperchlorination of the systemwas
ordered and done on the plumbing system.
January and April 2013, frequency of system testing for
biocide levels was increased from once a week to twice then
three times a week. ClO2 stock solution concentrations were
increased to .30 -.40ppm with a target stock tank solution
concentration of 250ppm. A schedule for ﬂushing less traf-
ﬁcked areas was implemented to eliminate dead zones. A
second thermal eradication was done. Intervention and
follow-up times ranged from one week to one month,
negatively impacting availability of rooms and sinks. An ac-
tion plan was created to optimize response including algo-
rithms for BMT/Heme and non-BMT/Heme patients.
Results: June 2013, action plan was complete. July results
were reviewed and communicated as directed by the plan.
All were negative. Action plan was presented, approved and
adopted as a standard procedure by both the BMT and hos-
pital Infection Prevention Committees in August 2013.164
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Problem: Absolute Neutrophil Counts (ANC) are hallmark
calculations for hematopoietic stem cell transplant (HSCT)
patients as a means to accurately measure infection risk and
monitor post-transplant engraftment. Historically, this
calculation was done solely using data from manual differ-
entials. Very low white blood cell counts (WBCs) seen in this
patient populationmake for unique challengeswith accuracy
due to lack of cells to count. Current advancements in ac-
curacy and speed of laboratory instruments posed a question
as to why manual differentials for ANC calculation were
necessary. Other factors were the turnaround times (TAT) for
manual differentials being double that of automated and
signiﬁcant cost difference between tests due to the labor
intensity of manual testing.
Intervention: A research study was performed using 275
specimens from ten different hematology/BMT patients over
a period of twomonths to compare the disparity in ANC from
the distinct differential types. The goal was to analyze ANC
calculations to determine if data supported a change in
practice to using automated differentials routinely.
Automated and manual differential results from each
specimen were independently reviewed by a medical tech-
nologist and transplant nurse to verify ANC calculations from
each source document. The calculations used were: Manual
ANC¼ [(%SEGS + % BANDS) xWBC] x 10; Automated ANC¼ [%
NE x WBC] x 10.
Results: Compilation of data showed the correlation factor
between calculated ANCs from automated and manual dif-
ferentials to be 93% when WBC was greater than 0.7 x 109/L.
For lower counts the instrument accuracy in counting cells
far exceeded that of the technologist as the instrument is
able to detect more white cells. Standard acceptable labora-
tory correlation for testing with different methods is 90% or
greater. Therefore, the calculated ANC results from an auto-
mated differential correspond to manual differential results
proving use of automated differentials for ANCs to be
warranted.
